Navigation Links
DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
Date:8/14/2009

lts in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including DOR201, orBec(R) and LPM(TM), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others m
'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
3. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
6. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
7. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
8. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
9. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
10. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
11. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... Companies" to their offering. This ... on technologies and applications. The report starts with ... estimation of markets. Technologies include array comparative genomic ...
(Date:9/2/2015)... , September 2, 2015 Biovista ... winners of the 2015 BeHEARD science challenge, a global ... rare disease researchers, access to the latest life science ... drug repositioning and pathway analytics capability to support ... Foundation in the study of Niemann-Pick Disease Type A ...
(Date:9/2/2015)... 2, 2015 Veracyte, Inc. (NASDAQ: VCYT ... president and chief executive officer, will present at the ... 2015 at 10:30 a.m. ET in New ... audio webcast and subsequent replay may be accessed by ... available shortly after conclusion of the presentation and archived ...
(Date:9/2/2015)... ... 02, 2015 , ... Whitehouse Laboratories is excited to announce ... Resources upcoming educational seminar and training session on Extractable & Leachable testing. Featuring ... provide Updates & Case Studies on the Latest Compliance Implications of USP and ...
Breaking Biology Technology:Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3
... DATATRAK International, Inc. (OTCQX: DATA), a technology and ... the clinical trials industry, today announced the addition ... Connect Partner Program.  The DATATRAK software suite complements ... processes using state-of-the-art clinical trial technology. ...
... TAIPEI, Taiwan, June 14, 2011 /PRNewswire-Asia/ -- TWi ... enrolled over 50% of the total 240 patients ... for the treatment of Type II Diabetes. The ... designed to evaluate the glycated hemoglglobin A1c (HbA1c) ...
... Twenty-two of America,s most promising scientists have been ... by The Pew Charitable Trusts.  The 2011 Pew Scholars ... recipients of the Albert Lasker Medical Research Award and ... of Scholars is related to many human diseases ranging ...
Cached Biology Technology:Research Dynamics Becomes DATATRAK Connect Partner 2Research Dynamics Becomes DATATRAK Connect Partner 3Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes 222 of America's Most Promising Scientists Selected as 2011 Pew Scholars in the Biomedical Sciences 222 of America's Most Promising Scientists Selected as 2011 Pew Scholars in the Biomedical Sciences 322 of America's Most Promising Scientists Selected as 2011 Pew Scholars in the Biomedical Sciences 4
(Date:9/2/2015)... Security of data and assets has ... organizations, telecommunications, hospitals, as well as individuals. Keys, ... used to prevent unauthorised access. Technological advancements resulted ... could gain access to secure premises after being ... devices and numeric codes. However, hackers also could ...
(Date:9/1/2015)... Calif. , Sept. 1, 2015  Automation ... travelers during airport passenger screening. This is the ... passenger screening process will become unintrusive. An assortment ... based on voluntary background investigations will transform the ... Frost & Sullivan, Global Airport Passenger Screening ...
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends & ... The Saudi Arabia Biomedical Sensors market is estimated ... 3.64% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology News(10 mins):Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2
... in medicine. In the future, new tissue grown in a ... the place of damaged cells in the brain. Rather than ... and complicated scientific issues, scientists have been looking to adult ... stem cells are now being cultivated from various tissues in ...
... many serious diseases remain a mystery? In considering that ... School of Medicine has come up with a unified molecular ... may provide an answer. Reviewing findings from multiple ... and Molecular Medicine and Investigator with the Howard Hughes Medical ...
... Texas University of Texas Medical Branch at Galveston researchers ... which the Ebola Zaire virus infects cells a critical ... produced by the virus. Ebola produces severe and often ... close to 90 percent in some outbreaks. No vaccine or ...
Cached Biology News:Tel Aviv University researchers create new stem cell screening tool 2Do 68 molecules hold the key to understanding disease? 2Scientists uncover Ebola cell-invasion strategy 2
... use of small interfering RNA (siRNA) molecules ... interference (RNAi) pathway have generated tremendous interest ... siRNA for experimental use can be synthesized ... then transfected into the target cells in ...
... 12™ is an automated hybridization system for ... automates both the hybridization and post hybridization ... A single instrument can process up to ... and has multi-protocol software, enabling the user ...
... Uncover the biological data hidden in your samples ... manufacturing allows you to create your own microarray ... at your own pace and receive delivery of ... eArray is a secure, online array creation application ...
... the demands of the routine trace metal ... reliable, robust and simple to use instrumentation. ... the most challenging sample matrices found in ... to the toughest analytical challenges found in ...
Biology Products: